1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

Shuren Steps Down As US FDA Device Center Director

 
• By Elizabeth Orr

Shuren is retiring after 15 years as head of the FDA Center for Devices and Radiological Health.

CDRH Director Jeff Shuren in his office
Shuren will leave the federal government after 28 years of service. • Source: Ferdous Al-Faruque

Jeff Shuren, the longtime director of the US Food and Drug Administration’s Center for Devices and Radiological Health, plans to retire at the end of the month after 15 years in the position, he announced 23 July.

Shuren has led CDRH since 2009 and overseen several key initiatives, including an overhaul of the clinical trials program, the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

Podium Policy Returns To US FDA, Or Is It Podcast Policy?

 
• By Michael McCaughan

US FDA critics have long decried the practice of using informal communications to convey regulatory expectations as podium policy. In the Makary era, the phrase may need to be updated because the agency now seems to be specializing in policy by podcast.

Branch Chief Vijay Kumar Named Acting Head Of US FDA’s Cell, Gene Therapy Office

 
• By Derrick Gingery

Kumar takes over as acting director of the Center for Biologics Evaluation and Research’s Office of Therapeutic Products days after director Nicole Verdun was ousted.

AI Will Bolster, Not Squelch, Patient Voice In Clinical Research, US FDA Says

 
• By Sue Sutter

Artificial intelligence tools used for clinical research should be developed with input from patients and focus on their needs and abilities, FDA experts said.

US FDA’s Top Cell and Gene Therapy Regulators Forced Out

 
• By Sarah Karlin-Smith

Office of Therapeutic Products Director Nicole Verdun and her deputy Rachael Anatol were escorted out of FDA headquarters on June 18. Disagreements over CAR-T regulation and Capricor’s DMD treatment may be to blame.

More from Agency Leadership